allogeneic

Type: Keyphrase
Name: allogeneic
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Stem Cell Therapy Market to grow at a CAGR of 39.5% to reach $330 Million by 2020.

Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020: Order report by ... [Published MyNewsDesk - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

RTI Surgical posts stronger-than-expected revenues in second quarter

RTI Surgical reported that revenues exceeded expectations in the second quarter on the strength of growth in spine and orthopedic fixation sales and international business.The $66 million in revenues exceeded prior revenue guidance of $62 million to $63 ... [Published Gainesville Sun - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

CardioCell Begins Phase IIa Clinical Trial Using itMSC Therapy to Treat Chronic Heart Failure HF Due to Non-Ischemic Cardiomyopathy

By a News Reporter-Staff News Editor at Biotech Week CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that creates allogeneic stem-cell therapies for cardiovascular indications, starts its Phase IIa clinical trial for chronic heart failure ... [Published Pharmacy Choice - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Surgeon joins staff

SHARON, PA.Board certified general surgeon, Dr. Mark Roth, recently joined the medical staff of Sharon Regional Health System. He is associated with general surgeon specialists Drs. Ravi Sachdeva, Gene Marcelli, and Sheetal Nijhawan.Dr. Roth specializes ... [Published Vindy.com - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Minimally invasive bone forming product ALLOB in Phase I/IIa trial for delayed union fracture

Bone Therapeutics, the regenerative therapy company addressing unmet medical needs in the field of bone diseases and orthopaedics, announced that the first patient has been treated with its novel allogeneic osteoblastic (bone-forming) cell therapy product ... [Published Express Pharma - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 4 reports

Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation Report of 2 Cases

Background: It is unknown whether the reduction in HIV-1 reservoirs seen after allogeneic hematopoietic stem cell transplantation (HSCT) with susceptible donor cells is sufficient to achieve sustained HIV-1 remission.Objective: To characterize HIV-1 ... [Published Annals of Internal Medicine - Jul 22 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Canine tumor cell and allogeneic dendritic cell fused vaccine and method for preparing the same

The present invention provides a dendritic cell-based vaccine by fusing a canine tumor cell and an allogeneic dendritic cell, and a method for preparing the same. The fusion cells expressing canine tumor antigens are generated by fusing canine bone marrow-derived ... [Published Free Patents Online - Jul 15 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 2 reports

CardioCell Launches Phase 2a Chronic Heart Failure Trial

CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that creates allogeneic stem-cell therapies for cardiovascular indications, started its Phase 2a clinical trial for chronic heart failure (HF) patients with non-ischemic cardiomyopathy. This ... [Published Drug Discovery and Development - Jul 08 2014]
First reported Jul 03 2014 - Updated Jul 04 2014 - 2 reports

Bone marrow transplantation shows potential for treating adults with severe sickle cell disease

Current ratings for: Ratings require JavaScript to be enabled.Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease, according to a study in JAMA .Myeloablative ... [Published Medical News Today - Jul 03 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Massachusetts General Hospital Details Findings in Stem Cells (Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem...

Massachusetts General Hospital Details Findings in Stem Cells (Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation)By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report ... [Published HispanicBusiness.com - Jul 02 2014]
First reported Jul 01 2014 - Updated Jul 02 2014 - 2 reports

Bone Marrow Surgery Performed at JIPMER

PUDUCHERRY: The Department of Medical Oncology, JIPMER, has successfully performed the first allogeneic bone marrow transplant (BMT) on a 17-year-old girl with relapsed acute lymphoblastic leukemia. The allogeneic BMT involves using the bone marrow from ... [Published New Indian Express - Jul 02 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

First Clinical Trial in Allogeneic Bone Cell Therapy Product

Minimally invasive bone forming product ALLOB® in Phase I/IIa trial for delayed union fracture30-06-2014: Bone Therapeutics announced that the first patient has been treated with its novel allogeneic osteoblastic (bone-forming) cell therapy product ALLOB® ... [Published Bionity.com - Jun 30 2014]

Quotes

...He suggested scientists can use HSCT "as a model for cure research [to] see if we can develop some therapies that mimic what we're doing with bone marrow transplantation."
The "Wound Care Market (Traditional Wound Care, Advanced Wound Care, Active Wound Care, Negative Pressure Wound Therapy & Other Therapy Devices) - Current Trends, Opportunities & Global Forecasts (2011 - 2016)" analyzes and studies the major market drivers, restraints, and opportunities in Americas, Europe, Asia, and Rest of the World
...Ching-Hon Pui from St Jude Children's Research Hospital in Memphis, Tennessee told Reuters Health by email. "Therefore, early treatment response during remission induction as measured by minimal residual disease (MRD) level should be determined for each patient. Post-remission treatment should be intensified for patients with positive MRD at the end of induction."
"We made progress in meeting the goals we shared in our first-quarter earnings press release -- recovery and growth in our sports and spine businesses, traction in surgical specialties and expanded distribution of map3 cellular allogeneic bone graft" President and CEO Brian Hutchison said in a news release

More Content

All (299) | News (235) | Reports (0) | Blogs (53) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
Batu Biologics Strategy for FDA Approval of Lun... [Published CW Atlanta - 57 mins ago]
Cell-Based Assay Market By Product, ... [Published EFYTimes.com - Jul 26 2014]
Neurocognitive Disorder Rates Differ by US vs L... [Published National AIDS Treatment Advocacy Project - Jul 26 2014]
No Detectable HIV RNA or DNA in 2 Bone Marrow T... [Published National AIDS Treatment Advocacy Project - Jul 26 2014]
Cell-Based Assay Market by Product, Application... [Published PRWeb - Jul 26 2014]
BCM Engineers Virus-Specific T Cells Against 5 ... [Published Bioresearch Online - Jul 25 2014]
Stem Cell Therapy Market to grow at a CAGR of 3... [Published MyNewsDesk - Jul 25 2014]
Blood Donor Deferral among Students in Northern... [Published Sexual Development - Jul 25 2014]
Wound Care Devices Market (Traditional Wound Ca... [Published Individual.com - Jul 25 2014]
TiGenix announces the clinical development of C... [Published Ysios Capital Partners - Jul 25 2014]
European Medicines Agency renews Marketing Auth... [Published Ysios Capital Partners - Jul 25 2014]
Minimal Residual Disease-Based Tx in Kids With ... [Published General Medicine eJournal - Jul 24 2014]
Asterias Biotherapeutics Announces Live Investo... [Published Bio-Medicine - Jul 24 2014]
Asterias Biotherapeutics Announces Live Investo... [Published Wall Street Business Network - Jul 24 2014]
RTI Surgical's (RTIX) CEO Brian Hutchison on Q2... [Published Seeking Alpha - Jul 24 2014]
Malcolm K. Brenner receives Pioneer Award for a... [Published Bio-Medicine - Jul 24 2014]
RTI Surgical posts stronger-than-expected reven... [Published Gainesville Sun - Jul 24 2014]
Advanced Biologics publishes additional OsteoAM... [Published TickerTech.com - Jul 24 2014]
Malcolm K Brenner, MD, PhD Receives Pioneer Awa... [Published Prlog - Jul 24 2014]
Merck Says First Patient Enrolled In Phase 3 Cl... [Published RTTNews.com - Jul 24 2014]
RTI Surgical™ Announces 2014 Second Quarter Res... [Published Wall Street Select - Jul 24 2014]
MEDICAL SCIENCES : Leading Clinician-Scientist ... [Published 4 Traders - Jul 24 2014]
Sangamo Biosciences' (SGMO) CEO Edward Lanphier... [Published Seeking Alpha - Jul 24 2014]
AASTROM BIOSCIENCES : Patent Application Titled... [Published 4 Traders - Jul 24 2014]
Patent Issued for Extracellular Matrix Cancer V... [Published HispanicBusiness.com - Jul 24 2014]
CardioCell Begins Phase IIa Clinical Trial Usin... [Published Pharmacy Choice - Jul 23 2014]
Surgeon joins staff [Published Vindy.com - Jul 22 2014]
Regeneus's human cancer vaccine pipeline adds a... [Published Pharma Letter - Jul 22 2014]
Minimally invasive bone forming product ALLOB i... [Published Express Pharma - Jul 22 2014]
Pluristem Therapeutics Sees Significant Decreas... [Published American Banking News - Jul 22 2014]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
CardioCell Begins Phase IIa Clinical Trial Usin... [Published EON Science - Jul 08 2014]
SAN DIEGO--(EON: Enhanced Online News)--Biotech startup CardioCell starts its Phase IIa clinical trial using adult, allogeneic stem-cell therapies to treat chronic heart failure patients with non-ischemic cardiomyopathy. ...
CardioCell Begins Phase IIa Clinical Trial Usin... [Published Business Wire Science: Science News - Jul 08 2014]
SAN DIEGO--(BUSINESS WIRE)--Biotech startup CardioCell starts its Phase IIa clinical trial using adult, allogeneic stem-cell therapies to treat chronic heart failure patients with non-ischemic cardiomyopathy. ...
CardioCell Begins Phase IIa Clinical Trial Usin... [Published Business Wire Health News - Jul 08 2014]
SAN DIEGO--(BUSINESS WIRE)--Biotech startup CardioCell starts its Phase IIa clinical trial using adult, allogeneic stem-cell therapies to treat chronic heart failure patients with non-ischemic cardiomyopathy. ...
Research and Markets: EpiCast Report: Graft-Ver... [Published Business Wire Health News - Jul 04 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dsdfsr/epicast_report) has announced the addition of the "EpiCast Report: Graft-Versus-Host Disease - Epidemiology Forecast to 2023" report to their offering. Graft-versus-host ...
Using Stem Cell Transplants to Boost Thymic Fun... [Published Fight Aging! - Jun 30 2014]
The thymus is a gateway for the production of new T cells , the immune cells responsible for destroying pathogens and precancerous or senescent cells . The thymus is highly active in childhood, churning out a large supply of these immune cells ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
TiGenix announces the clinical development of C... [Published GlobeNewswire: Advertising News - Jun 30 2014]
Immunicum’s abstract with data from a kidney ca... [Published GlobeNewswire: Acquisitions News - Mar 27 2014]
Immunicum reports promising preclinical results... [Published GlobeNewswire: Advertising News - Mar 06 2014]
POSITIVE SPINAL DISC REPAIR TRIAL RESULTS USING... [Published GlobeNewswire: Advertising News - Jan 29 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.